Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Angiotensin Ii. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 5/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL29361852 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL29394721 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL21811603 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL31477824 | 0.99 | AGTR2 (0.98) | AGTR2AGTR1 | |
| SCHEMBL28485749 | 0.97 | AGTR2 (0.94) | AGTR2AGTR1 | |
| SCHEMBL29619824 | 0.97 | AGTR2 (0.94) | AGTR2AGTR1 | |
| [Val5] - Angiotensin Ii SCHEMBL31572111 | 0.97 | AGTR2 (0.94) | AGTR2AGTR1 | |
| Acetic Acid SCHEMBL21811310 | 0.96 | AGTR2 (0.92) | AGTR2AGTR1 | |
| SCHEMBL31332289 | 0.95 | AGTR2 (0.91) | AGTR2AGTR1 | |
| Angiotensin-Ii SCHEMBL34470359 | 0.95 | AGTR2 (0.90) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125858-B1 | NUTRITIONAL COMPOSITION COMPRISING L-CARNITINE TARTRATE FOR USE IN TREATING OR PREVENTING A CORONAVIRUS INFECTION IN A MAMMAL | LONZA GREENWOOD LLC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-3907507-B1 | COLORIMETRIC SENSOR FOR DETECTING BACTERIA AND/OR VIRUSES | DG GROUP S P A (IT) | 2026-04-15 | — | — | EP | claimed |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-3922714-B1 | USE OF 3D SKIN MODEL FOR ASSESSING TREATMENT OF SARS-CORONAVIRUS SKIN INFECTION | PKDERM (FR) | 2026-04-01 | — | — | EP | claimed |
| US-12516145-B2 | Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization | NORTHWESTERN UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| US-20250389717-A1 | METHODS FOR ASSESSING MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE PATIENTS | PROMETHEUS LABORATORIES INC (US) | 2025-12-25 | — | — | US | claimed |
| EP-3893890-B1 | GINSENOSIDE M1 FOR USE IN THE TREATMENT OF DAMAGES IN ORGANS OR TISSUES IN A SUBJECT CAUSED BY INFECTION WITH CORONAVIRUS | LEE SHEAU LONG (TW) | 2025-12-10 | — | — | EP | claimed |
| EP-4226157-B1 | METHOD FOR DETERMINING WHETHER OR NOT VIRUS-NEUTRALIZING ANTIBODIES ARE PRESENT AND IN VITRO METHOD FOR SCREENING COMPOUNDS FOR THEIR ABILITY TO NEUTRALIZE A VIRUS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2025-12-03 | — | — | EP | claimed |
| WO-2025245481-A1 | METHODS AND MATERIALS FOR TREATING CARDIAC CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250336657-A1 | Calibration Method, Analysis Method, Controller, and Analyzer | SHIMADZU CORP (JP) | 2025-10-30 | — | — | US | claimed |
| WO-2022132666-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022125947-A1 | METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS AND COMPOSITIONS THEREOF | GARUDA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| US-20220184114-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-06-16 | — | — | US | claimed |
| WO-2022115609-A1 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | claimed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3986536-A1 | NEUROMODULATION DEVICE | Galvani Bioelectronics Limited (GB) | 2022-04-27 | — | — | EP | claimed |
| WO-2022082082-A2 | LUNG TREATMENT COMPOSITIONS | LEHRMAN SHERWOOD RUSS (US) | 2022-04-21 | — | — | WO | claimed |
| US-20220082563-A1 | METHODS FOR ASSESSING MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS | PROMETHEUS LABORATORIES INC. | 2022-03-17 | — | — | US | claimed |
| US-11274134-B2 | Compositions for treatment of vascular disease | HOUSTON GENE THERAPEUTICS LLC (US) | 2022-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250389717-A1 | METHODS FOR ASSESSING MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE PATIENTS | MMP9, TIMP3, MMP13 | AGTR1 4471/4885AGTR2 4481/4885 |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR1, CXCR2, CCR2 | AGTR1 242/4885AGTR2 526/4885 |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | AGTR1 292/4885AGTR2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.